Menu

Peanut Allergy Treatment Works Long Term

Four years after taking a probiotic and peanut protein for 18 months, two-thirds of children in a small clinical trial can eat peanuts with no health issues.

Aug 17, 2017
Jef Akst

FLICKR, AIRPIXIn 2013, researchers at Murdoch Children’s Research Institute in Australia dosed 48 children either with a probiotic with increasing amounts of a peanut protein, a treatment known as PPOIT, or with a placebo once daily for a year and a half. This week (August 15), they reported that some 70 percent of the participants who received PPOIT can ingest peanut-containing foods with no adverse reactions, according to a study published in The Lancet Child & Adolescent Health.

That result represents only a slight dip from the original results that found 82 percent of the treated children could tolerate peanuts one month after finishing their PPOIT courses, suggesting the treatment is the first long-lasting option for those who suffer from a peanut allergy.

“These children had been eating peanut freely in their diet without having to follow any particular program of peanut intake in the years after treatment was completed,” lead researcher Mimi Tang says in a statement sent to The Scientist. “This is a major step forward in identifying an effective treatment to address the food allergy problem in Western societies.”

The probiotic used was Lactobacillus rhamnosus, a bacterium that may help mitigate allergic symptoms. “The probiotic acts on the immune system, encourages the immune system to generate a protective, or tolerance, response rather than allergy,” says Tang, according to ABC. “When given regularly over time, we hope to see the immune system recognise the antigen.” The next step is to trial PPOIT in a larger study. 

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.